Literature DB >> 1747275

Vascular tone in heart failure: the neuroendocrine-therapeutic interface.

J G Cleland1, C M Oakley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1747275      PMCID： PMC1024719          DOI： 10.1136/hrt.66.4.264

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


× No keyword cloud information.
  36 in total

1.  Effect of prazosin vs placebo on chronic left ventricular heart failure.

Authors:  W S Aronow; M Lurie; M Turbow; K Whittaker; S Van Camp; D Hughes
Journal:  Circulation       Date:  1979-02       Impact factor: 29.690

2.  Phentolamine for vasodilator treatment of severe heart-failure.

Authors:  P A Majid; B Sharma; S H Taylor
Journal:  Lancet       Date:  1971-10-02       Impact factor: 79.321

3.  Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside.

Authors:  M A Fifer; W S Colucci; B H Lorell; B E Jaski; W H Barry
Journal:  J Am Coll Cardiol       Date:  1985-03       Impact factor: 24.094

4.  Central and regional hemodynamic effects and neurohumoral consequences of minoxidil in severe congestive heart failure and comparison to hydralazine and nitroprusside.

Authors:  R V Markham; A Gilmore; W A Pettinger; D C Brater; J R Corbett; B G Firth
Journal:  Am J Cardiol       Date:  1983-10-01       Impact factor: 2.778

5.  Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.

Authors:  C V Leier; P Huss; R D Magorien; D V Unverferth
Journal:  Circulation       Date:  1983-04       Impact factor: 29.690

6.  Prazosin and congestive heart failure: short- and long-term therapy.

Authors:  J L Rouleau; J W Warnica; J H Burgess
Journal:  Am J Med       Date:  1981-07       Impact factor: 4.965

7.  Angiotensin-induced myocardial necrosis and renal failure in the rabbit: distribution of lesions and severity in relation to plasma angiotensin II concentration and arterial pressure.

Authors:  D Kremer; G Lindop; W C Brown; J J Morton; J I Robertson
Journal:  Cardiovasc Res       Date:  1981-01       Impact factor: 10.787

8.  Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise.

Authors:  J R Wilson; N Ferraro
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

9.  Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo.

Authors:  J A Franciosa; K T Weber; T B Levine; G T Kinasewitz; J S Janicki; J West; M M Henis; J N Cohn
Journal:  Am Heart J       Date:  1982-09       Impact factor: 4.749

10.  Effects of physical training in chronic heart failure.

Authors:  A J Coats; S Adamopoulos; T E Meyer; J Conway; P Sleight
Journal:  Lancet       Date:  1990-01-13       Impact factor: 79.321
View more
  8 in total

1.  A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.

Authors:  M Ligueros; R Unwin; M R Wilkins; J Humphreys; S J Coles; J Cleland
Journal:  Clin Auton Res       Date:  1992-12       Impact factor: 4.435

2.  Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition.

Authors:  Manuel Gutiérrez-Aguilar; Diana L Douglas; Anne K Gibson; Timothy L Domeier; Jeffery D Molkentin; Christopher P Baines
Journal:  J Mol Cell Cardiol       Date:  2014-04-21       Impact factor: 5.000

Review 3.  Neuroendocrine activation after myocardial infarction: causes and consequences.

Authors:  J G Cleland; P J Cowburn; K Morgan
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 4.  Optimising heart failure pharmacotherapy: the ideal combination.

Authors:  J G Cleland; D P Dutka
Journal:  Br Heart J       Date:  1994-08

Review 5.  The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.

Authors:  R I Cargill; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

6.  Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure.

Authors:  L Murray; I B Squire; J L Reid; K R Lees
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

Review 7.  Role of antithrombotic agents in heart failure.

Authors:  John G F Cleland; Saqib Mumtaz; Luca Cecchini
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

8.  IP3 receptor orchestrates maladaptive vascular responses in heart failure.

Authors:  Haikel Dridi; Gaetano Santulli; Jessica Gambardella; Stanislovas S Jankauskas; Qi Yuan; Jingyi Yang; Steven Reiken; Xujun Wang; Anetta Wronska; Xiaoping Liu; Alain Lacampagne; Andrew R Marks
Journal:  J Clin Invest       Date:  2022-02-15       Impact factor: 14.808
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.